- Title: Subtitle
- Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
- Creators
- Samuel Yamshon - Weill Cornell MedicineJean L. Koff - Emory UniversityMelissa C. Larson - Mayo Clinic in FloridaBrad S. Kahl - Washington University in St. LouisCarla Casulo - University of RochesterIzidore S. Lossos - Sylvester Comprehensive Cancer CenterSara Haddadi - Sylvester Comprehensive Cancer CenterMichele D. Stanchina - Sylvester Comprehensive Cancer CenterDai Chihara - The University of Texas MD Anderson Cancer CenterAmy A. Ayers - The University of Texas MD Anderson Cancer CenterThomas M. Habermann - Mayo ClinicYucai Wang - Mayo ClinicArushi Khurana - Mayo ClinicGrzegorz S. Nowakowski - Mayo ClinicTanner W Reicks - Mayo Clinic in FloridaUmar Farooq - University of IowaBrian K. Link - University of IowaJonathon B. Cohen - Emory UniversityPeter Martin - Weill Cornell MedicineJia LiAshwini ShewadeConnie Lee BatleviAndrea Lo-RossiDavid FoxAnthony MasaquelYong MunJames R. Cerhan - Mayo Clinic in FloridaChristopher R. Flowers - The University of Texas MD Anderson Cancer CenterMatthew J. Maurer - Mayo Clinic in FloridaLoretta Nastoupil - The University of Texas MD Anderson Cancer Center
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.144(Supplement 1), pp.3093-3093
- DOI
- 10.1182/blood-2024-208111
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Publisher
- ELSEVIER
- Grant note
- Burroughs Wellcome FundTakedaPfizerPharmacyclics/JanssenCellectisBostonGeneAbbVieBeiGeneTG TherapeuticsJanssen PharmaceuticalsGenMabRoche/GenentechAbbvieCaribou BiosciencesGenmabDaiichi SankyoGenentechIncyte CorporationADC Therapeutics
Consultancy, Research Funding; Burroughs Wellcome Fund: Research Funding; Takeda: Research Funding; Pfizer: Research Funding; Pharmacyclics/Janssen: Consultancy; Seagen: Consultancy; Spectrum: Consultancy; Gilead: Consultancy, Research Funding; Cellectis: Research Funding; BostonGene: Research Funding; AbbVie: Consultancy, Research Funding; BeiGene: Consultancy; Bayer: Consultancy, Research Funding; TG Therapeutics: Research Funding; Denovo Biopharma: Consultancy; Iovance: Research Funding; Janssen Pharmaceuticals: Research Funding; AstraZeneca: Consultancy. Maurer: GenMab: Re-search Funding; Roche/Genentech: Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advi-sory committees; BMS: Consultancy, Research Funding. Nastoupil: Gilead Sciences/Kite Pharma: Honoraria, Research Fund-ing; Abbvie, BMS, Caribou Biosciences, Genentech, Genmab, Gilead/Kite, Janssen, Incyte, Ipsen, Merck, Novartis, Regen-eron, Takeda: Consultancy; Caribou Biosciences: Honoraria, Research Funding; Daiichi Sankyo: Honoraria, Research Funding; Genentech: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Denovo Biopharma: Honoraria; Novartis: Hon-oraria, Research Funding; Genmab: Honoraria, Research Funding; Merck: Honoraria, Research Funding; Incyte Corporation: Honoraria; Janssen: Honoraria, Research Funding; Regeneron: Consultancy, Honoraria; BMS, Caribou Biosciences, Daiichi Sankyo, Genentech, Genmab, Gilead/Kite, Janssen, Incyte, Ipsen, Merck, Novartis, Takeda: Research Funding; Takeda: Con-sultancy, Honoraria, Research Funding; AbbVie: Honoraria; ADC Therapeutics: Honoraria; Abbvie, BMS, Caribou Biosciences, Daiichi Sankyo, Genentech, Genmab, Gilead/Kite, Janssen, Incyte, Ipsen, Novartis, Takeda: Honoraria.
- Language
- English
- Date published
- 11/05/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984770786802771
Abstract
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
Blood, Vol.144(Supplement 1), pp.3093-3093
11/05/2024
DOI: 10.1182/blood-2024-208111
Details
Metrics
9 Record Views